Potentially significant drug interactions of class III antiarrhythmic drugs

Drug Safety

Volumn 26, Issue 6, 2003, Pages 421-438

  Yamreudeewong, Weeranuj ^a,b   DeBisschop, Michael ^a   Martin, Linda G ^a   Lower, Dennis L ^b  

^a UNIVERSITY OF WYOMING   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CARBAMAZEPINE; CISAPRIDE; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; DOFETILIDE; DOLASETRON MESILATE; ETHOSUXIMIDE; FLECAINIDE; FOSPHENYTOIN SODIUM; IBUTILIDE; LIDOCAINE; MEGESTROL; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; PROCHLORPERAZINE; PROTEINASE INHIBITOR; QUINIDINE; QUINOLONE DERIVATIVE; SOTALOL; SULFAMETHOXAZOLE; TRIMETHOPRIM; VERAPAMIL; WARFARIN;

ATAXIA; BLEEDING; BRADYCARDIA; CARDIOTOXICITY; CATION TRANSPORT; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INDUCTION; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERREFLEXIA; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY TUBULE ABSORPTION; MEMBRANE TRANSPORT; NEUROTOXICITY; NYSTAGMUS; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK ASSESSMENT; SEIZURE; SOMNOLENCE; TOXICITY; TREMOR; URINARY EXCRETION;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BRETYLIUM COMPOUNDS; DRUG INTERACTIONS; HUMANS; PHENETHYLAMINES; SOTALOL; SULFONAMIDES;

EID: 0037693766     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326060-00004     Document Type: Review

References (83)

1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-47
2. Tatro DS, editor. Drug interaction facts. St Louis: Facts and Comparisons: A Wolters Kluwer Company, 2002
3. Blaufarb I, Pfeifer TM, Frishman WH. Beta-blockers drug interactions of clinical significance. Drug Saf 1995; 13 (6): 359-70
4. Rosenthal T, Ezra D. Calcium antagonists: drug interactions of clinical significance. Drug Saf 1995; 13 (3): 157-87
5. Rees A, Dalal JJ, Reid PG, et al. Dangers of amiodarone and anticoagulant treatment. BMJ 1981; 282: 1756-7
6. Martinowitz U, Robinovich J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981; 304: 671-2
7. Singhvi SM, Duchin KL, Willard DA, et al. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32: 182-9
8. Drummer OH, Thompsom J, Hooper R, et al. Effect of probenecid on the disposition of captopril and captopril dimer in the rat. Biochem Pharmacol 1985; 34: 3347-51
9. Tatro DS. Drug interactions. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach 4th ed. Stamford: Appleton and Lange, 1999: 35-49
10. Stockley IH. General considerations and an outline survey of some basic interaction mechanisms In: Stockley IH, editor. Drug interactions. 4th edition. London: The Pharmaceutical Press, 1996: 1-15
11. Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmaco-dynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmcol 2000; 41: 715-22
12. Rieder MJ, Spino M. The theophylline-erythromycin interaction. J Asthma 1988; 25: 195-204
13. Matheny CJ, Lamb MW, Brouwer KLR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96
14. Hunter J, Hirst BH. Intestinal secretion of drugs: the role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Del 1997; 25: 129-57
15. Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430-6
16. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610-7
17. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280: 67-71
18. Hutchison TA, Shahan DR, Anderson ML, editors. Drugdex system. Greenwood Village (CO): Micromedex Inc.,
19. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69-110
20. Brendorp B, Pedersen O, Torp-Pedersen C, et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 2002; 25 (12): 847-65
21. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, et al. Amiodarone: what we have learned from clinical trials? Clin Cardiol 2000; 23: 73-82
22. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112
23. Leor J, Levartowsky D, Sharon C, et al. Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988; 116: 206-7
24. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268-75
25. Nitsch J, Luderitz B. Acceleration of amiodarone elimination by cholestyrarnine. Dtsch Med Wochenschr 1986; 111: 1241-4
26. Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J 1985; 109: 163-4
27. Lubic SP, Nguyen KPV, Dave B, et al. Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovas Pharmacol 1994; 24: 707-14
28. Wagner JA, Weisman HF, Levine JH, et al. Differential effects of amiodarone and desmethylamiodarone on calcium antagonist receptors. J Cardiovasc Pharmacol 1990; 15: 501-7
29. Product Information. Propulsid® cisapride. Titusville (NJ): Janssen Pharmaceutica Inc., 2000
30. Nattel S, Singh BN. Evolution, mechanism, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999; 84: 11R-9R
31. Nicolau D, Uber W, Crumbley III AJ, et al. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992; 11: 564-8
32. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840-7
33. Klein HO, Beker B, DiSegni E, et al. Asystole produced by the combination of amiodarone and digoxin. Am Heart J 1987; 113: 399-400
34. Nademanee K, Kannan R, Hendrickson J, et al. Amiodaronedigoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111-6
35. Maragno I, Santostasi G, Gaion RM, et al. Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. Int J Clin Pharm Res 1984; 4: 149-53
36. Santostasi G, Fantin M, Maragno I, et al. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. J Cardiovasc Pharmacol 1987; 9: 385-90
37. Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988; 148: 745-6
38. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161-6
39. Nolan Jr PE, Marcus FI, Hoyer GL, et al. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 1989; 46: 43-50
40. McGovern B, Geer VR, LaRaia PJ, et al. Possible interaction between amiodarone and phenytoin. Ann Intern Med 1984; I01: 650-1
41. Nolan Jr PE, Marcus FI, Karol MD, et al. Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol 1990; 30: 1112-9
42. Product Information. Tikosyn [(TM)] dofetilide. New York (NY): Pfizer Inc., 1999
43. Product Information. Tambocor [(TM)] flecainide acetate. St Paul (MN): 3M Pharmaceuticals, 1997
44. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256-69
45. Product Information. Corvert® ibutilide fumarate injection. Kalamazoo (MI): Upjohn Company, 1998
46. Keidar S, Grenadier E, Palant A. Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration. Am Heart J 1982; 104: 1384-5
47. Siegmund J, Wilson J, Imhoff T. Amiodarone interaction with lidocaine. J Cardiovasc Pharmacol 1993; 21: 513-5
48. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983; 106: 924-30
49. Windle J, Prystowsky EN, Miles WM, et al. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 1987; 41: 603-10
50. Product Information. Betapace AF[(TM)] sotalol hydrochloride. Wayne, (NJ): Berlex Laboratories, 2000
51. Product Information. Agenerase® amprenavir. Triangle Park (NC), Glaxo Wellcome Inc. Research, 2000
52. Product Information. Viracept® nelfinavir mesylate. La Jolla (CA): Agouron Pharmaceuticals Inc., 1999
53. Product Information. Norvir® ritonavir. North Chicago (IL): Abbott Laboratories, 1999
54. Lohman JJ, Reichert LJ, Degen LP. Antiretroviral therapy increases serum concentrations of amiodarone [letter]. Ann Pharmacother 1999; 33: 645-6
55. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779-81
56. Rotmensch HH, Belhassen B. Amiodarone in the management of cardiac arrhythmias: current concepts. Med Clin North Am 1988; 72: 321-58
57. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985; 28: 257-61
58. Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58: 43-51
59. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol 1985; 28: 625-9
60. Product Information. Tequin® gatifloxacin. Princeton (NJ): Bristol-Myers Squibb Company, (PI revised 2000 Aug) reviewed 2001 Jan
61. Product Information. Avelox™ moxifloxacin hydrochloride. West Haven (CT): Bayer Corporation, (PI revised 2000 Nov) reviewed 2001 Mar
62. Product Information. Zagam® sparfloxacin. Collegeville (PA): Rhone-Poulenc Rorer Pharmaceuticals Inc., (PI revised 1998 Oct) reviewed 2001 May
63. Product Information. Anzemet® dolasetron. Kansas City (MO): Hoechst Marion Roussel Inc., 1997
64. Product Information. Orap® pimozide. Sellersville (PA): Gate Pharmaceuticals, 1999
65. Tsikouris JP, Cox CD. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 2001; 21: 1514-29
66. Efacts CD-ROM for Windows. St Louis (MO): Facts and comparisons: 2002 Oct
67. Chandrasekaran S, Steinberg JS. Efficacy of bretylium tosylate for ventricular tachycardia. Am J Cardiol 1999; 83: 115-7, A9
68. Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 1996; 41: 77-81
69. Product Information. Geodon® ziprasidone. New York (NY): Pfizer Inc., 2001
70. Auer J, Berent R, Weber T, et al. Current and new drugs for the treatment of arrhythmias. Curr Opin Investig Drugs 2002; 3: 1029-36
71. Matyus P, Varro A, Papp JG, et al. Antiarrhythmic agents: current status and perspectives. Med Res Rev 1997; 17: 427-51
72. Abel S, Nichols DJ, Brearley CJ, et al. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 2000; 49: 64-71
73. Elliott HL, McLean K, Sumner DJ, et al. Immediate cardiovascular responses to oral prazosin: effects of concurrent betablockers Clin Pharmacol Ther 1981; 29: 303-9
74. Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982; 13: 865-70
75. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol 1997; 43: 269-72
76. Warren R, Vohra J, Hunt D, et al. Serious interactions of sotalol with amiodarone and flecainide [letter]. Med J Aust 1990; 152: 277
77. Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. Am Coll Cardiol 2002; 39: 517-20
78. Saarimaa H. Combination of clonidine and sotalol in hypertension. BMJ 1976; 1 (6013): 810
79. Bailey RR, Neale TJ. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. BMJ 1976; 1: 942-3
80. Singh S, Saini RK, DiMarco J, et al. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol 1991; 68: 1227-30
81. Skehan JD, Barnes JN, Drew PJ, et al. Hypokalaemia induced by a combination of a beta-blocker and a thiazide. BMJ 1982; 284: 83
82. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984; 51: 157-62
83. Tian R, Koyabu N, Takanaga H, et al. Effect of grapefruit juice and orange on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802-9